Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date-Reference-Cited by-同舟云学术

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date

Published:2021-01 Issue: Volume:Volume 15 Page:331-338
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Dorey-Stein Zachariah L^ORCID,Shenoy Kartik V

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference33 articles.

1. Global asthma prevalence in adults: findings from the cross-sectional world health survey

2. Severe asthma—A population study perspective

3. Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma

4. Anaptysbio reports top-line data from interim analysis of eclipse phase 2 clinical trial of etokimab in chronic rhinosinusitis with nasal polyps; 2020. Available from: https://www.globenewswire.com/Website. Accessed September 13, 2020.

5. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy;Clinical Reviews in Allergy & Immunology;2024-07-12

2. Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity;Frontiers in Pharmacology;2024-01-08

3. Eosinophils—from cradle to grave;Allergy;2023-09-13

4. The Role of Eosinophil-Derived Neurotoxin and Vascular Endothelial Growth Factor in the Pathogenesis of Eosinophilic Asthma;Cells;2023-05-06

5. A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention;Frontiers in Immunology;2023-03-31